Compare Citius Pharmaceuticals Inc (CTXR) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs McCormick & Company, Incorporated — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.79M), while McCormick & Company, Incorporated trades at $45.62 (market cap $12.20B). The key difference: McCormick & Company, Incorporated is far larger — about 884.7× Citius Pharmaceuticals Inc's market cap, and McCormick & Company, Incorporated pays a 4.24% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and McCormick & Company, Incorporated for 67 Days on average.
| CTXR | MKC | |
|---|---|---|
Market Cap | $13.79M | $12.20B |
Volume | 156,684 | 4,117,008 |
Sector | Health | Consumer Staples |
52-Week High | $1.82 | $71.65 |
52-Week Low | $0.48 | $44.14 |
Typical Hold Time | 16 Days | 67 Days |
Enterprise Value | $3.96M | $16.88B |
Dividend Yield | — | 4.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, but remains in a bearish technical trend with negative profitability metrics. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR sales, though net income margin remains deeply negative at -651.27%. Analyst consensus is strongly bullish with 5 buy ratings and a $5.00 price target, representing significant upside potential from current levels.
While CTXR shows promising commercial progress with its oncology drug launch, the stock faces substantial execution risks due to persistent losses and cash burn. The bullish analyst sentiment contrasts with weak fundamentals, creating a high-risk, high-reward scenario for investors betting on successful commercialization of LYMPHIR in the $400M+ CTCL market.
MKC trades at $45.94, up 1.19% today, with a bearish technical signal but strong fundamentals. Recent Q3 2026 earnings beat estimates with $0.86 EPS, driven by 17% sales growth and margin expansion. The stock appears undervalued with a P/E of 8.18 and offers a dividend yield. Cash flow trends show operational strength despite a net outflow in 2025.
The outlook is mixed: solid earnings growth and a $53.50 consensus price target suggest upside, but technical weakness and competitive pressures pose risks. Investor sentiment is cautious with a 'Hold' analyst consensus. Key catalysts include continued margin improvement and integration of recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
